Keyword: GW Pharmaceuticals
GW Pharma may be the first drugmaker to launch a cannabis-based drug in the U.S., but it's unlikely to be the last—and that's why so many are watching.
What's on Tuesday's talking points memo at JPM? Drug launches, hoped-for FDA nods, deals, rivalries, FDA tea leaves—and one unexpected tax bill.
FSD Pharma taps competing prescription CBD company GW Pharma’s former top marketing executive to serve as its new CEO.
The first FDA-approved CBD product launched Thursday in the form of GW Pharmaceuticals' cannabinoid Epidiolex, which treats rare epilepsy.
GW Pharmaceutical is looking to assure doctors that epilepsy treatment Epidiolex is vastly different from off-the-shelf artisan oils at cannabis shops.
GW Pharma hasn't been able to launch its FDA-approved cannabidiol drug Epidiolex, but with a DEA move this week, the company can plan its rollout.
The FDA just approved Epidiolex, the cannabis-based drug that GW Pharma has been toiling over for years, to treat two rare and serious forms of epilepsy.